Distinct cortical immune-signaling profiles in autism spectrum disorder and severe mental illness

The human brain is not an isolated organ; it exists in a constant, quiet conversation with the body's immune system. While we often think of immunity as the defense force that fights off infections in the blood, the brain has its own version of this system. Specialized cells within the brain act as sentinels, releasing chemical signals called cytokines to manage inflammation, repair damage, and even help wire the brain's connections during development. When this communication goes wrong, it can lead to a state of chronic, low-level inflammation that researchers suspect plays a role in several serious brain conditions. Two of the most prominent of these are autism spectrum disorder, a neurodevelopmental condition affecting how people connect with the world, and severe mental illnesses like schizophrenia and bipolar disorder, which involve profound disruptions in thinking and mood. For years, scientists have wondered if these very different conditions might share a common root cause: a brain that is stuck in a state of inflammation. If they did, it would suggest that the same biological mechanism drives both, potentially pointing toward a single type of treatment for all.

To test this idea, a team of researchers at the University of California, Davis, decided to look directly at the brain tissue itself, rather than relying on blood tests or theories. They focused on a specific region called the superior temporal gyrus, an area known to be involved in processing sound and social interaction, which is often altered in both autism and severe mental illness. The team gathered brain samples from seventy-two people who had donated their bodies to science after passing away. This group included twenty-nine people with no history of psychiatric illness, seventeen people diagnosed with autism, and twenty-six people diagnosed with severe mental illness, a category that included schizophrenia, bipolar disorder, and related conditions. Using a sensitive technique that can measure dozens of proteins at once, the researchers analyzed forty-eight different immune-related chemicals in these brain samples. They were looking for a specific pattern: a shared "signature" of inflammation that would appear in both the autism group and the severe mental illness group, confirming the theory of a common inflammatory state.

What they found, however, was not a shared signature, but two distinct and contrasting stories. The brain tissue from the individuals with autism revealed a very specific pattern of immune activity. It was not a general, widespread inflammation affecting every part of the immune system. Instead, the changes were centered on a particular family of signaling molecules related to a protein called IL-1. In the autism group, levels of IL-1α, IL-18, and a growth factor called FLT-3L were significantly higher than in both the healthy controls and the severe mental illness group. The researchers also found elevated levels of M-CSF, a protein that helps support the maintenance of immune cells in the brain. This combination suggests that in autism, the brain is not just inflamed; it is actively engaging specific pathways that support the development and upkeep of immune cells, alongside a targeted inflammatory response. It is a selective, organized alteration rather than a chaotic, general fire.

In contrast, the brain tissue from the severe mental illness group told a different story. This group did not show the same broad elevation of the IL-1 family proteins seen in autism. Instead, their most prominent difference was a single, sharp increase in a protein called eotaxin. While the autism group showed a complex web of changes involving multiple proteins, the severe mental illness group was defined by this specific marker, along with a few other subtle shifts. When the researchers used advanced statistical methods to look at the entire profile of proteins together, the three groups—healthy controls, autism, and severe mental illness—stood apart from one another clearly. The data showed that while both clinical groups had altered immune signaling compared to healthy brains, the nature of that alteration was fundamentally different. The idea that these conditions share a single, uniform inflammatory state was ruled out by the evidence; instead, each condition appears to have its own unique immune profile.

The study also looked at how these immune signals changed as people aged. In healthy brains, certain proteins like eotaxin and FGF-2 tended to rise in a predictable way as people got older. However, this pattern was disrupted in both the autism and severe mental illness groups. For instance, the relationship between age and eotaxin was weaker in the clinical groups than in the healthy controls. This suggests that the way the brain's immune system interacts with the aging process is altered in these conditions, but again, the alteration is not the same for both. The researchers noted that their findings in the brain tissue did not always match what is seen in blood tests. For example, while blood studies sometimes show high levels of IL-1β in autism, this protein was too rare in their brain samples to measure reliably, and they found high levels of IL-1α instead. This highlights a crucial point: what happens in the blood does not necessarily reflect what is happening inside the brain.

Ultimately, these findings refine our understanding of how the immune system relates to brain disorders. They confirm that neuroimmune signaling is indeed altered in both autism and severe mental illness, but they reject the notion that this is a shared, generic problem. Instead, the brain in autism seems to be navigating a path of selective immune-cell support and specific inflammatory signaling, while the brain in severe mental illness follows a different trajectory, marked by distinct chemical changes like elevated eotaxin. These results suggest that while the immune system is a point of convergence for these diverse conditions, the specific ways it goes awry are condition-specific. This distinction is vital because it implies that a treatment designed to lower general inflammation might not work for everyone, and that future therapies may need to target the unique immune signatures of each disorder. The study provides a clearer, more nuanced map of the brain's immune landscape, showing that even when different conditions seem to share a common theme of inflammation, the melody each plays is entirely its own.